These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19710283)

  • 21. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT; Findik D; Senkeles C; Arslan U
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
    Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
    J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.
    Taj-Aldeen SJ; Kolecka A; Boesten R; Alolaqi A; Almaslamani M; Chandra P; Meis JF; Boekhout T
    Infection; 2014 Apr; 42(2):393-404. PubMed ID: 24352810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.
    Miranda-Zapico I; Eraso E; Hernández-Almaraz JL; López-Soria LM; Carrillo-Muñoz AJ; Hernández-Molina JM; Quindós G
    J Antimicrob Chemother; 2011 Oct; 66(10):2315-22. PubMed ID: 21795259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
    Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center.
    Marcos-Zambrano LJ; Escribano P; Sánchez C; Muñoz P; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4565-72. PubMed ID: 24867979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia.
    Amran F; Aziz MN; Ibrahim HM; Atiqah NH; Parameswari S; Hafiza MR; Ifwat M
    J Med Microbiol; 2011 Sep; 60(Pt 9):1312-1316. PubMed ID: 21459913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
    Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
    Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
    Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.
    Pfaller MA; Espinel-Ingroff A; Bustamante B; Canton E; Diekema DJ; Fothergill A; Fuller J; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Ostrosky-Zeichner L; Pelaez T; St-Germain G; Turnidge J
    Antimicrob Agents Chemother; 2014; 58(2):916-22. PubMed ID: 24277027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
    Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
    J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.